Recursion Pharmaceuticals (RXRX) Gross Profit (2022 - 2025)
Historic Gross Profit for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q3 2025 value amounting to -$9.5 million.
- Recursion Pharmaceuticals' Gross Profit fell 16792.83% to -$9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.8 million, marking a year-over-year decrease of 21278.71%. This contributed to the annual value of $13.6 million for FY2024, which is 58415.49% up from last year.
- Per Recursion Pharmaceuticals' latest filing, its Gross Profit stood at -$9.5 million for Q3 2025, which was down 16792.83% from -$938000.0 recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Gross Profit registered a high of $14.0 million during Q3 2024, and its lowest value of -$9.5 million during Q3 2025.
- Moreover, its 5-year median value for Gross Profit was $1.0 million (2023), whereas its average is -$10526.3.
- Within the past 5 years, the most significant YoY rise in Recursion Pharmaceuticals' Gross Profit was 417063.95% (2024), while the steepest drop was 91663.37% (2024).
- Quarter analysis of 5 years shows Recursion Pharmaceuticals' Gross Profit stood at $2.5 million in 2021, then rose by 11.96% to $2.8 million in 2022, then plummeted by 64.39% to $1.0 million in 2023, then tumbled by 916.63% to -$8.2 million in 2024, then decreased by 15.32% to -$9.5 million in 2025.
- Its last three reported values are -$9.5 million in Q3 2025, -$938000.0 for Q2 2025, and -$7.1 million during Q1 2025.